Statistics from Altmetric.com
I read with interest the paper by Vital et al,1 a pilot study testing the efficacy of an extra dose of rituximab (completing 3×1000 mg over 4 weeks) in comparison with the standard-dose regimen (2×1000 mg) in rheumatoid arthritis patients with incomplete depletion of B cells after a first 1000 mg dose of rituximab (RTX). The study represents an advance in the knowledge about the effects of RTX, but I have some concerns about the interpretation …
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.